Somatostatin treatment of gastrointestinal fistulas: evidence for a rebound effect on withdrawal.
Three patients with external fistulas from the gastrointestinal tract were treated with somatostatin, a peptide which inhibits pancreatic, gastric and intestinal secretion. Although somatostatin reduced fistula output in two patients and possibly prevented haemorrhage in one, it did not induce fistula closure in any; moreover on withdrawal of somatostatin one patient developed life threatening gastrointestinal haemorrhage and a transient fistula hypersecretion occurred in the others. This experience of somatostatin treatment was less favourable than that previously reported in other small series. Positive nitrogen balance was probably not maintained during treatment in the three patients reported here and in one patient in a previous study in whom somatostatin was ineffective; the peptide may only promote fistula closure in adequately nourished patients.
D000009:Abdominal Muscles; D000368:Aged; D005260:Female; D005747:Gastric Fistula / Q000188:drug therapy*; D005750:Gastric Juice / Q000187:drug effects / Q000378:metabolism; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D007412:Intestinal Fistula / Q000188:drug therapy*; D007419:Intestinal Secretions / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013004:Somatostatin / Q000009:adverse effects / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome
D013004:Somatostatin